Wedbush Rates Viridian Therapeutics (VRDN) buy, $43 Price Target
Wedbush has reaffirmed its buy rating on Viridian Therapeutics, setting a price target of $43, a 128.85% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $43 price target on June 30, 2026.
Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).
VRDN
Viridian Therapeutics, Inc.
Key Points
- On June 30, 2026, Wedbush reiterated its buy rating on Viridian Therapeutics (VRDN) with a target price of $43.
- Currently, shares are trading at $18.79, well below the target, indicating potential upside for investors.
- The average target price from analysts for VRDN is $36.62, suggesting a generally positive outlook from Wall Street.
Get $VRDN trade alerts by text
We text you when insiders, Congress or big funds trade $VRDN. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures
Wedbush Maintains Positive Outlook on VRDN
Wedbush has reaffirmed its buy rating on Viridian Therapeutics, Inc. (VRDN) on June 30, 2026, setting a price target of $43. This reflects confidence in the company's growth prospects as shares currently trade at $18.79 on the NasdaqCM.
Wedbush vs. the S&P 500
Hypothetical returns from Wedbush's disclosed trades, not real profit or advice. How we model this.
How This Call Compares with Other Ratings
Wedbush's target of $43 is notably optimistic compared to the average target price of $36.62 from 16 analysts covering the stock. Other firms have also issued ratings; for instance, RBC Capital maintains an Outperform rating with targets ranging from $35 to $38, while Truist Securities has a Buy rating with targets of $38 and $39. This consistent support from multiple analysts suggests a favorable sentiment towards Viridian Therapeutics.
Stock Performance Context
As of the latest trading session, VRDN shares are significantly below their 52-week high of $34.29, which indicates they may be undervalued at the current price. The stock has traded between $13.18 and $34.29 over the past year, reflecting volatility but also potential for recovery as analysts remain bullish.
$VRDN price target
Viridian Therapeutics, Inc. daily closes and this analyst's $43 target. Not advice.
Recent Earnings
In its latest earnings report, Viridian Therapeutics reported revenue of $71.1 million, showing a growth rate of 2.8%. The next earnings report is expected on November 5, 2026, which may provide further insight into the company's financial health and growth trajectory.
What VRDN Does
Viridian Therapeutics focuses on developing treatments for serious and rare diseases, particularly in the biotechnology sector. Its innovative therapies target conditions like thyroid eye disease, positioning the company for potential breakthroughs in the healthcare market.
What to Watch at VRDN
Investors should keep an eye on the upcoming earnings report in November, which could impact future analyst ratings and stock performance. As a reminder, the latest ratings reflect analyst positions as of June 30, 2026, and may not represent current views.
Related Filing Alerts
Source: Wedbush's rating change on $VRDN (Jun 30, 2026). Written by software, not financial advice. How we make alerts